VcR-CVAD induction chemotherapy followed by maintenance rituximab produces durable remissions in mantle cell lymphoma: a Wisconsin Oncology Network study

Conclusions Long-term outcomes with VcR-CVAD are comparable with more intensive inductions and consolidation approaches. MCL is biologically heterogeneous and durable remission can be achieved with intermediate intensity therapy. Maintenance rituximab appears to contribute to these excellent outcomes. Teaser VcR-CVAD with maintenance rituximab is an intermediate-intensity regimen for older and younger mantle cell lymphoma (MCL) patients. Thirty patients were treated, with primary end point of response and secondary endpoints of progression-free and overall survival. After a median follow-up of 7.8 years, no relapses were observed beyond 6 years. VcR-CVAD has long-term outcomes comparable with more intensive chemotherapy regimens.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research